<DOC>
	<DOCNO>NCT02432053</DOCNO>
	<brief_summary>The objective study demonstrate safety efficacy once-daily Advagraf adult population undergo kidney liver transplantation India .</brief_summary>
	<brief_title>A Study Demonstrate Safety Efficacy Advagraf Patients Undergoing Kidney Liver Transplantation India</brief_title>
	<detailed_description>This phase IV , multi-centre , open label prospective study daily Advagraf 200 patient undergoing kidney liver transplantation India . Adult patient undergo kidney liver transplantation meeting eligibility criterion enrol study . Enrolled patient administer daily dose Advagraf 12 week . During 12 week total 9 regular visit undertake .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion Criteria ( common kidney liver transplant patient ) : Male female patient 18 65 year age , undergo liver kidney transplantation Female patient child bear potential must negative serum pregnancy test prior enrolment must agree practice effective birth control study . Tacrolimus may reduce clearance steroid base contraceptive lead increase hormone exposure ; particular care exercise decide upon contraceptive measure . Patients capable understanding purpose risk study , provide write informed consent participate study . Inclusion Criteria ( specifically kidney transplant patient ) : Patients end stage kidney disease suitable candidate primary kidney transplantation . Patients schedule receive kidney transplant cadaveric living donor 5 65 year age compatible ABO blood type . Inclusion Criteria ( specifically liver transplant patient ) : Patients end stage liver disease suitable candidate primary liver transplantation . Patients schedule receive liver transplant cadaveric living donor 5 65 year age compatible ABO blood type . Exclusion Criteria ( common kidney liver transplant patient ) : Previously receive scheduled receive organ transplant kidney liver Undergoing retransplant either cadaveric living donor Contraindication use tacrolimus corticosteroid . Malignancy history malignancy within last 5 year , except nonmetastatic basal squamous cell carcinoma skin treat successfully . Systemic infection require treatment . Transplantation kidney liver nonheart beat donor . Severe diarrhea , active peptic ulcer gastrointestinal disorder may affect absorption tacrolimus . Any form substance abuse , psychiatric disorder condition , opinion investigator , may complicate communication patient . Simultaneously participate another investigational drug study participate study within 28 day prior entry study . Receiving nonregistered medication receive nonregistered medication within 28 day prior entry study . Pregnant woman breastfeed mother . Patients respective donor know positive human immunodeficiency virus ( HIV ) . Unlikely comply visit schedule protocol . Exclusion criterion ( Specifically kidney transplant patient ) Cold ischemia time donor kidney &gt; 30 hour . High immunological risk , define positive cross match PRA grade 50 % previous 6 month . Liver cirrhosis . Significant liver disease , define either elevate serum glutamic pyruvic transaminase / alanine aminotransferase ( SGPT / ALT ) ( least 2.5 time upper value normal range investigational site ) elevate serum glutamic oxaloacetic transaminase/ aspartate transaminase ( SGOT/AST ) ( least 2.5 time upper value normal range investigational site ) elevate total bilirubin level ( least 2.5 time upper value normal range investigational site ) 28 day prior entry study . Patients respective donor know positive hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Exclusion Criteria ( specifically liver transplant patient ) : Transplanted hepatocellular carcinoma single nodule great 5.0 cm diameter 3 nodule metastasis vascular tumoral invasion . Serum creatinine 2mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>FK506</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Transplantation</keyword>
</DOC>